The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dobrzanski, M. J.
Right arrow Articles by Dutton, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dobrzanski, M. J.
Right arrow Articles by Dutton, R. W.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Lung Cancer
The Journal of Immunology, 1999, 162: 6671-6680.
Copyright © 1999 by The American Association of Immunologists

Therapeutic Effects of Tumor-Reactive Type 1 and Type 2 CD8+ T Cell Subpopulations in Established Pulmonary Metastases1

Mark J. Dobrzanski, Joyce B. Reome and Richard W. Dutton2

Trudeau Institute, Saranac Lake, NY 12983

Cytolytic CD8+ T cells fall into two subpopulations based on cytokine-secretion. Type 1 CD8+ cells (Tc1) characteristically secrete IFN-{gamma}, whereas type 2 CD8+ cells (Tc2) secrete IL-4 and IL-5. We assessed the relative therapeutic effects of adoptively transferred OVA-specific Tc1 and Tc2 CD8+ cells in mice bearing established OVA-transfected B16 melanoma lung metastases. Both Tc1 and Tc2 subpopulations mediated a reduction in lung tumor growth that subsequently prolonged survival times in mice with both early (day 7) and more advanced (day 14) levels of tumor development. CD8+ T cell populations recovered from spleens of tumor-bearing mice receiving Tc1 or Tc2 cells showed markedly enhanced tumor Ag-specific cytolytic and cytokine-releasing activities that correlated with delays in tumor cell growth and progression. Initially, both tumor-reactive Tc1 and Tc2 effector cells accumulated at the tumor site with nearly equal frequency. Tc1 cells persisted, whereas Tc2 cell numbers progressively diminished over time. Titration of Tc1 and Tc2 effector cells showed that protection was dose dependent with the former being 5-fold more effective. Tc2 cells achieved a comparable reduction in lung tumor cell growth at higher concentrations of cell transfer. Tc1 effectors from IFN-{gamma}-deficient mice were less therapeutically effective than wild-type mice, but there was no significant reduction in activity between corresponding Tc2 populations. We speculate that the effectiveness of Tc1 and Tc2 cells may depend on different mechanisms. These studies suggest a potential role for Tc1 and Tc2 CD8+ subpopulations in tumor regression and immunotherapy.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
H. Hamada, M. d. l. L. Garcia-Hernandez, J. B. Reome, S. K. Misra, T. M. Strutt, K. K. McKinstry, A. M. Cooper, S. L. Swain, and R. W. Dutton
Tc17, a Unique Subset of CD8 T Cells That Can Protect against Lethal Influenza Challenge
J. Immunol., March 15, 2009; 182(6): 3469 - 3481.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. B. F. Werneck, G. Lugo-Villarino, E. S. Hwang, H. Cantor, and L. H. Glimcher
T-Bet Plays a Key Role in NK-Mediated Control of Melanoma Metastatic Disease
J. Immunol., June 15, 2008; 180(12): 8004 - 8010.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Z. Li, F. Pradera, T. Kammertoens, B. Li, S. Liu, and Z. Qin
Cross-Talk between T Cells and Innate Immune Cells Is Crucial for IFN-{gamma}-Dependent Tumor Rejection
J. Immunol., August 1, 2007; 179(3): 1568 - 1576.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Sasaki, X. Zhu, C. Vasquez, F. Nishimura, J. E. Dusak, J. Huang, M. Fujita, A. Wesa, D. M. Potter, P. R. Walker, et al.
Preferential Expression of Very Late Antigen-4 on Type 1 CTL Cells Plays a Critical Role in Trafficking into Central Nervous System Tumors
Cancer Res., July 1, 2007; 67(13): 6451 - 6458.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. A. Casey and M. F. Mescher
IL-21 Promotes Differentiation of Naive CD8 T Cells to a Unique Effector Phenotype
J. Immunol., June 15, 2007; 178(12): 7640 - 7648.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
A. Boissonnas, L. Fetler, I. S. Zeelenberg, S. Hugues, and S. Amigorena
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor
J. Exp. Med., February 19, 2007; 204(2): 345 - 356.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Iezzi, A. Boni, E. Degl'Innocenti, M. Grioni, M. T. S. Bertilaccio, and M. Bellone
Type 2 Cytotoxic T Lymphocytes Modulate the Activity of Dendritic Cells Toward Type 2 Immune Responses
J. Immunol., August 15, 2006; 177(4): 2131 - 2137.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. P. Zoeteweij, D. E. Epperson, J. D. Porter, C. X. Zhang, O. Y. Frolova, A. P. Constantinides, S. R. Fuhrmann, M. El-Amine, J.-H. Tian, L. R. Ellingsworth, et al.
GM1 Binding-Deficient Exotoxin Is a Potent Noninflammatory Broad Spectrum Intradermal Immunoadjuvant
J. Immunol., July 15, 2006; 177(2): 1197 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Nishimura, J. E. Dusak, J. Eguchi, X. Zhu, A. Gambotto, W. J. Storkus, and H. Okada
Adoptive Transfer of Type 1 CTL Mediates Effective Anti-Central Nervous System Tumor Response: Critical Roles of IFN-Inducible Protein-10.
Cancer Res., April 15, 2006; 66(8): 4478 - 4487.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Olver, P. Groves, K. Buttigieg, E. S. Morris, M. L. Janas, A. Kelso, and N. Kienzle
Tumor-Derived Interleukin-4 Reduces Tumor Clearance and Deviates the Cytokine and Granzyme Profile of Tumor-Induced CD8+ T Cells
Cancer Res., January 1, 2006; 66(1): 571 - 580.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Gao, J. Tao, M. O. Li, D. Zhang, H. Chi, O. Henegariu, S. M. Kaech, R. J. Davis, R. A. Flavell, and Z. Yin
JNK1 Is Essential for CD8+ T Cell-Mediated Tumor Immune Surveillance
J. Immunol., November 1, 2005; 175(9): 5783 - 5789.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S.-i. Hiraoka, N. Takeuchi, Y. Bian, H. Nakahara, M. Kogo, K. Dunussi-Joannopoulos, S. Wolf, S. Ono, and H. Fujiwara
B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors
Int. Immunol., August 1, 2005; 17(8): 1071 - 1079.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Kienzle, S. Olver, K. Buttigieg, P. Groves, M. L. Janas, A. Baz, and A. Kelso
Progressive Differentiation and Commitment of CD8+ T Cells to a Poorly Cytolytic CD8low Phenotype in the Presence of IL-4
J. Immunol., February 15, 2005; 174(4): 2021 - 2029.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Li, A. L. Carr, E. J. Donald, J. J. Skitzki, R. Okuyama, L. M. Stoolman, and A. E. Chang
Synergistic Effects of IL-12 and IL-18 in Skewing Tumor-Reactive T-Cell Responses Towards a Type 1 Pattern
Cancer Res., February 1, 2005; 65(3): 1063 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Xystrakis, P. Cavailles, A. S. Dejean, B. Cautain, C. Colacios, D. Lagrange, M.-J. van de Gaar, I. Bernard, D. Gonzalez-Dunia, J. Damoiseaux, et al.
Functional and Genetic Analysis of Two CD8 T Cell Subsets Defined by the Level of CD45RC Expression in the Rat
J. Immunol., September 1, 2004; 173(5): 3140 - 3147.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
C. S. Chin, C. H.T. Miller, L. Graham, M. Parviz, S. Zacur, B. Patel, A. Duong, and H. D. Bear
Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes
Int. Immunol., September 1, 2004; 16(9): 1283 - 1294.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. A. Hollenbaugh, J. Reome, M. Dobrzanski, and R. W. Dutton
The Rate of the CD8-Dependent Initial Reduction in Tumor Volume Is Not Limited by Contact-Dependent Perforin, Fas Ligand, or TNF-Mediated Cytolysis
J. Immunol., August 1, 2004; 173(3): 1738 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Yamaguchi, S.-i. Hiraoka, T. Mukai, N. Takeuchi, X.-Y. Zhou, S. Ono, M. Kogo, K. Dunussi-Joannopoulos, V. Ling, S. Wolf, et al.
Induction of Tumor Regression by Administration of B7-Ig Fusion Proteins: Mediation by Type 2 CD8+ T Cells and Dependence on IL-4 Production
J. Immunol., February 1, 2004; 172(3): 1347 - 1354.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, and R. W. Dutton
Tc1 and Tc2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses
J. Immunol., February 1, 2004; 172(3): 1380 - 1390.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, J. C. Hylind, and R. W. Dutton
Effector Cell-Derived Lymphotoxin {alpha} and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases
Cancer Res., January 1, 2004; 64(1): 406 - 414.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. A. O'Mara and P. M. Allen
Pulmonary Tumors Inefficiently Prime Tumor-Specific T Cells
J. Immunol., January 1, 2004; 172(1): 310 - 317.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
T. Schuler, S. Kornig, and T. Blankenstein
Tumor Rejection by Modulation of Tumor Stromal Fibroblasts
J. Exp. Med., November 17, 2003; 198(10): 1487 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Lavergne, B. Combadiere, O. Bonduelle, M. Iga, J.-L. Gao, M. Maho, A. Boissonnas, P. M. Murphy, P. Debre, and C. Combadiere
Fractalkine Mediates Natural Killer-Dependent Antitumor Responses in Vivo
Cancer Res., November 1, 2003; 63(21): 7468 - 7474.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
U. Jung, J. E. Foley, A. A. Erdmann, M. A. Eckhaus, and D. H. Fowler
CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects
Blood, November 1, 2003; 102(9): 3439 - 3446.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. F. Kircher, J. R. Allport, E. E. Graves, V. Love, L. Josephson, A. H. Lichtman, and R. Weissleder
In Vivo High Resolution Three-Dimensional Imaging of Antigen-Specific Cytotoxic T-Lymphocyte Trafficking to Tumors
Cancer Res., October 15, 2003; 63(20): 6838 - 6846.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. E. Oran and H. L. Robinson
DNA Vaccines, Combining Form of Antigen and Method of Delivery to Raise a Spectrum of IFN-{gamma} and IL-4-Producing CD4+ and CD8+ T Cells
J. Immunol., August 15, 2003; 171(4): 1999 - 2005.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Schuler and T. Blankenstein
Cutting Edge: CD8+ Effector T Cells Reject Tumors by Direct Antigen Recognition but Indirect Action on Host Cells
J. Immunol., May 1, 2003; 170(9): 4427 - 4431.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. M. Jensen, S. L. Meijer, R. A. Kurt, W. J. Urba, H.-M. Hu, and B. A. Fox
Regression of a Mammary Adenocarcinoma in STAT6-/- Mice Is Dependent on the Presence of STAT6-Reactive T Cells
J. Immunol., February 15, 2003; 170(4): 2014 - 2021.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. P. Rubinstein, A. N. Kadima, M. L. Salem, C. L. Nguyen, W. E. Gillanders, M. I. Nishimura, and D. J. Cole
Transfer of TCR Genes into Mature T Cells Is Accompanied by the Maintenance of Parental T Cell Avidity
J. Immunol., February 1, 2003; 170(3): 1209 - 1217.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. P. Rubinstein, A. N. Kadima, M. L. Salem, C. L. Nguyen, W. E. Gillanders, and D. J. Cole
Systemic Administration of IL-15 Augments the Antigen-Specific Primary CD8+ T Cell Response Following Vaccination with Peptide-Pulsed Dendritic Cells
J. Immunol., November 1, 2002; 169(9): 4928 - 4935.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. O. Gollnick, L. Vaughan, and B. W. Henderson
Generation of Effective Antitumor Vaccines Using Photodynamic Therapy
Cancer Res., March 1, 2002; 62(6): 1604 - 1608.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. Reynolds, V. A. Norgan, U. Bhambra, J. Smith, H. T. Cook, and C. D. Pusey
Anti-CD8 Monoclonal Antibody Therapy Is Effective in the Prevention and Treatment of Experimental Autoimmune Glomerulonephritis
J. Am. Soc. Nephrol., February 1, 2002; 13(2): 359 - 369.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. B. Faries, I. Bedrosian, S. Xu, G. Koski, J. G. Roros, M. A. Moise, H. Q. Nguyen, F. H. C. Engels, P. A. Cohen, and B. J. Czerniecki
Calcium signaling inhibits interleukin-12 production and activates CD83+ dendritic cells that induce Th2 cell development
Blood, October 15, 2001; 98(8): 2489 - 2497.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Dobrzanski, J. B. Reome, and R. W. Dutton
Role of Effector Cell-Derived IL-4, IL-5, and Perforin in Early and Late Stages of Type 2 CD8 Effector Cell-Mediated Tumor Rejection
J. Immunol., July 1, 2001; 167(1): 424 - 434.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Winter, H.-M. Hu, K. McClain, W. J. Urba, and B. A. Fox
Immunotherapy of Melanoma: A Dichotomy in the Requirement for IFN-{{gamma}} in Vaccine-Induced Antitumor Immunity Versus Adoptive Immunotherapy
J. Immunol., June 15, 2001; 166(12): 7370 - 7380.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. K. Helmich and R. W. Dutton
The Role of Adoptively Transferred CD8 T Cells and Host Cells in the Control of the Growth of the EG7 Thymoma: Factors That Determine the Relative Effectiveness and Homing Properties of Tc1 and Tc2 Effectors
J. Immunol., June 1, 2001; 166(11): 6500 - 6508.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Seliger, U. Wollscheid, F. Momburg, T. Blankenstein, and C. Huber
Characterization of the Major Histocompatibility Complex Class I Deficiencies in B16 Melanoma Cells
Cancer Res., February 1, 2001; 61(3): 1095 - 1099.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
R. J. Hogan, E. J. Usherwood, W. Zhong, A. D. Roberts, R. W. Dutton, A. G. Harmsen, and D. L. Woodland
Activated Antigen-Specific CD8+ T Cells Persist in the Lungs Following Recovery from Respiratory Virus Infections
J. Immunol., February 1, 2001; 166(3): 1813 - 1822.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. A. Candido, K. Shimizu, J. C. McLaughlin, R. Kunkel, J. A. Fuller, B. G. Redman, E. K. Thomas, B. J. Nickoloff, and J. J. Mulé
Local Administration of Dendritic Cells Inhibits Established Breast Tumor Growth: Implications for Apoptosis-inducing Agents
Cancer Res., January 1, 2001; 61(1): 228 - 236.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
C. Vizler, N. Bercovici, A. Heurtier, N. Pardigon, K. Goude, K. Bailly, C. Combadiere, and R. S. Liblau
Relative Diabetogenic Properties of Islet-Specific Tc1 and Tc2 Cells in Immunocompetent Hosts
J. Immunol., December 1, 2000; 165(11): 6314 - 6321.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. E. Dixon, J. B. Mandac, P. J. Martin, R. C. Hackman, D. K. Madtes, and J. G. Clark
Adherence of adoptively transferred alloreactive Th1 cells in lung: partial dependence on LFA-1 and ICAM-1
Am J Physiol Lung Cell Mol Physiol, September 1, 2000; 279(3): L583 - L591.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Dobrzanski, J. B. Reome, and R. W. Dutton
Type 1 and Type 2 CD8+ Effector T Cell Subpopulations Promote Long-Term Tumor Immunity and Protection to Progressively Growing Tumor
J. Immunol., January 15, 2000; 164(2): 916 - 925.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Fallarino and T. F. Gajewski
Cutting Edge: Differentiation of Antitumor CTL In Vivo Requires Host Expression of Stat1
J. Immunol., October 15, 1999; 163(8): 4109 - 4113.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.